Indication intelligence, analysis and sector perception

Lower open expected …

December 24, 2015 6:54am

RegMed’s pre-open, it might seem to be all about buying the laggards but forget the sector, the markets and enjoy this time and our place in life – it’s Christmas …

Stocks close at 1 p.m. ET on Thursday and are closed for the Christmas holiday on Friday. Other markets including energy and bonds will also close early, shutting at 1:30 p.m. ET and 2 p.m. ET

I provide intelligence and analysis for short and near-term investment. Subscribe or take your losses without complaining …

Critical information ahead of “our” universe’s open!

DOW futures are FLAT at 0.0% and NASDAQ futures are DOWN -0.0%

U.S. stock index futures pointed to a lower open on Thursday amid light trade as investors prepare for a shortened trading day for the Christmas holiday.

European stocks traded lower, ahead of the Christmas holidays. The pan-European STOXX 600 traded around 0.2% lower. The German DAX and a number of other markets were closed today, with other bourses opened for a shortened trading day.

Asia stocks were mixed, dragged by declines on the mainland, knocking the region's Christmas cheer before the holiday period.

Data docket: There is weekly unemployment claims data due at 8:30 a.m. ET on Thursday, as well as natural gas inventories at 10:30 a.m.

The RegMed sector closed POSITIVE on Wednesday, NEGATIVE on Tuesday, POSITIVE on Monday, Friday and last Thursday.

Wednesday closed POSITIVE with 9 decliners, 32 advancers and 2 flats following Tuesday’s NEGATIVE close with 29 decliners, 13 advancers and 1 flat following Monday’s POSITIVE close with 15 decliners, 25 advancers and 3 flats;

You’ve made it to the office, turned on the monitor having just gotten your coffee and it hits you … what are today’s … trades?

Stem, cell and gene therapy RegMed (SCGT&RM) stocks closed higher Wednesday, the last full trading day of the week. Volatility was lower <15.5> versus Tuesday’s 16.5 although volume was higher.

It’s Christmas Eve, so trading is expected to be subdued …

I was truly surprised by Wednesday’s “movements”; I hadn’t expected much … its Christmas week and “players” are dispersing.

Merry Christmas … be safe if you are traveling!

Wednesday’s indications:

The Bottom Line ... to investing in the stem, cell and gene therapy RegMed sector requires in-depth research, a disciplined strategy – I call it being a little obsessive compulsive, attention to the real and perceived patterns which also hypes the vigilance. Only with all three will you find the wisdom to trim big winners before they fall or reverse course on losers before they get worse.

One way I consider myself different, however, is my willingness to own up to my miscues which if wrong are usually early!

Signing off for the holidays but, give yourself a personal present - the key to RegMed investing success – a SUBSCRIPTION to get all the information and intelligence … when you need it, the most!

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.